Identification of fucosylated Fetuin‐A as a potential biomarker for cholangiocarcinoma

Purpose Cholangiocarcinoma (CCA) is a malignancy of the bile ducts. The purpose of this discovery study was to identify effective serum markers for surveillance of cholangiocarcinoma. Experimental design Using a glycomic method, patients with CCA were determined to have increased levels of alpha‐1,3...

Full description

Saved in:
Bibliographic Details
Published in:Proteomics. Clinical applications 2017-09, Vol.11 (9-10), p.n/a
Main Authors: Betesh, Lucy, Comunale, Mary Ann, Wang, Mengjun, Liang, Hongyan, Hafner, Julie, Karabudak, Aykan, Giama, Nasra H., Moser, Catherine D., Miyoshi, Eiji, Roberts, Lewis R., Block, Timothy M., Mehta, Anand
Format: Article
Language:English
Subjects:
Bile
Bile ducts
Biomarkers
Ceruloplasmin
Cholangiocarcinoma
Cholangitis
Experimental design
Fetuin‐A
Glycan
Glycoproteins
Glycosylation
Hemopexin
Identification methods
Kininogens
Liver
Liver diseases
Malignancy
Patients
Proteins
Surveillance
Trypsin
α2-Macroglobulin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Cholangiocarcinoma (CCA) is a malignancy of the bile ducts. The purpose of this discovery study was to identify effective serum markers for surveillance of cholangiocarcinoma. Experimental design Using a glycomic method, patients with CCA were determined to have increased levels of alpha‐1,3 and alpha‐1,6 linked fucosylated glycan. Proteomic analysis of the serum fucosylated proteome identified proteins such as alpha‐2‐macroglobulin, kininogen, hemopexin, fetuin‐A, alpha‐1 anti‐trypsin, and ceruloplasmin as being hyperfucosylated in HCC. The levels of these glycoproteins in 109 patients with CCA, primary sclerosing cholangitis (PSC), and control patients were compared to the performance of CA‐19‐9, the current “gold standard” assay for cholangiocarcinoma. Results Fucosylated Fetuin‐A (fc‐Fetuin‐A) had the best ability to differentiate CCA from PSC, with an AUROC of 0.812 or 0.8665 at differentiating CCA from those with PSC or other liver disease. CA‐19‐9 had poor ability to differentiate PSC from cholangiocarcinoma (AUROC of 0.625). Conclusion and clinical relevance Using glycomic and proteomic methods we identified a set of proteins that contain altered glycan in the sera of those with CCA. One of these proteins, fucosylated Fetuin‐A may have value in the surveillance of people at risk for the development of cholangiocarcinoma.
ISSN:1862-8346
1862-8354
DOI:10.1002/prca.201600141